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Abstract
Purpose To evaluate the outcome of liver transplantation
for acute-on-chronic liver failure.
Patients and methods From November 1991 to December
2007, 517 patients underwent liver transplantation at
Queen Mary Hospital, Hong Kong. Among them, 149 had
acute-on-chronic liver failure as defined in the recent Asian
Pacific Association for the Study of Liver Consensus
Meeting. Their clinical data were reviewed and their sur-
vival outcomes were compared with those of patients who
underwent liver transplantation for fulminant hepatic fail-
ure and for cirrhosis only in the same period.
Results The patients with acute-on-chronic liver failure
included 50 patients having acute exacerbation of chronic
hepatitis B and 99 cirrhotic patients with acute deterioration.
Their median model for end-stage liver disease scores were
35 and 37, respectively. Preoperative infection (35%),
hepatorenal syndrome (38%), and respiratory failure
(28.8%) were common. One hundred and three patients
received living donor liver grafts and 46 patients received
deceased donor liver grafts. The hospital mortality rate was
4.7%. The 5-year survival rates were 93.2% for patients with
acute exacerbation of chronic hepatitis B and 90.5% for
cirrhotic patients with acute deterioration. The results were
similar to those of the patients with fulminant hepatic failure
(n = 37) and the patients having cirrhosis only (n = 301).
Conclusions Liver transplantation for acute-on-chronic
liver failure is life-saving, and the survival rates it attains
are similar to those attained by transplantation for other
liver conditions.
Keywords Acute-on-chronic liver failure 
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Introduction
Acute-on-chronic liver failure had been an ill-defined
condition until the recent Asian Pacific Association for the
Study of the Liver Consensus Meeting, which defined it as
‘‘acute hepatic insult manifesting as jaundice (serum bili-
rubin [5 mg/dl) and coagulopathy (international normal-
ized ratio [1.5), complicated within 4 weeks by ascites
and/or encephalopathy in a patient with previously diag-
nosed or undiagnosed chronic liver disease’’ [1]. The
prognosis is dismal when such patients develop multiorgan
failure. Liver transplantation is the only curative option
that can salvage them. However, data of liver transplanta-
tion for patients with acute-on-chronic liver failure are
scarce. In this article, we report the outcome of our patients
with such condition as defined in the consensus statement.
Patients and methods
From November 1991 to December 2007, 517 adult
patients (C17 years old) underwent liver transplantation at
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Queen Mary Hospital, The University of Hong Kong. All
of the liver explants were examined histologically. On the
basis of the explant pathology reports, the patients, other
than those with polycystic liver (n = 5), metabolic disease
(n = 7), or retransplantation for liver graft non-function
(n = 18), were categorized into four groups according to
their conditions: group 1, patients with fulminant hepatic
failure (n = 37); group 2, patients with acute exacerbation
of chronic hepatitis B (n = 50); group 3, cirrhotic patients
with acute deterioration (n = 99); and group 4, patients
with cirrhosis only (n = 301). Massive or submassive
hepatocyte necrosis was a prominent feature in the first two
conditions. Differentiating fulminant hepatic failure from
acute exacerbation of chronic hepatitis B was based on
findings of fibrous bands and ductular proliferation in the
latter condition. Cirrhosis was diagnosed on the basis of
typical findings of nodules enveloped by fibrous septae.
Differentiation between cirrhosis with acute deterioration
and cirrhosis only was based on the presence of hepatocyte
necrosis and features of acute hepatitis in the former con-
dition. Patients in groups 2 and 3 were those with acute-on-
chronic liver failure and the focus of this study.
Clinical records of these four groups of patients were
reviewed with the aim to ascertain that their clinical pre-
sentations did fulfill the definition of acute-on-chronic liver
failure as described in the Asian Pacific Association for the
Study of the Liver Consensus Meeting. Presence of
hyperbilirubinemia and coagulopathy was confirmed by
laboratory tests. Presence of ascites was documented by
imaging studies and/or laparotomy. Hepatic encephalopa-
thy was documented when there was disturbance in central
nervous system function and the severity was graded from
1 to 4 according to the system devised by Conn and Bircha
[2].
Patients in groups 1, 2, and 3 all presented clinical
features of acute liver failure. Once their clinical status
fulfilled the King’s College Hospital criteria [3] and con-
traindications to liver transplantation were ruled out, the
family was informed of the need for liver transplantation
and the options of deceased donor liver transplantation
(DDLT) and living donor liver transplantation (LDLT).
While waiting for a liver graft, supportive treatment was
continued. Lamivudine was given to patients with hepatitis
B immediately if they had not been on nucleoside ana-
logue. Patients with suspected infection were prescribed
with broad-spectrum antibiotics after appropriate cultures
had been performed. Only patients with positive bacterial
or fungal culture in blood, urine, sputum, bronchoalveolar
lavage fluid, or ascites were considered to have infection
before transplantation. Presence of infection was not con-
sidered a contraindication to liver transplantation. If the
condition of the patient was not critical, infection was
treated with potent antibiotic before transplantation.
Otherwise, heavy doses of broad-spectrum antibiotic were
administered perioperatively. Patients with oliguria or
rapidly deteriorating renal function received hemodialysis
or continuous venovenous hemofiltration. Thirteen patients
received molecular adsorbents recirculating system treat-
ment as well [4]. Endotracheal intubation and mechanical
ventilation were not routinely performed unless the patient
was comatose and control of airway was considered nec-
essary. Intracranial pressure was monitored in the first few
patients, but the monitoring was not done in the subsequent
patients because serious complications related to insertion
of intracranial pressure monitoring device were encoun-
tered. Instead, these patients were monitored by their
neurological signs, and workup for the recipients and living
donors (if available) was proceeded quickly to allow the
patients to receive transplantation in time [5]. Computed
tomography of the brain was routinely performed in all
patients with impaired conscious state to rule out severe
brain edema and intracranial bleeding, which were con-
traindications to liver transplantation.
Liver transplantation was performed with deceased
donor or living donor livers by the technique previously
described [6]. All deceased donor grafts were whole grafts
except 6, which were right trisegment grafts derived from
splitting of livers. All, except 2, living donor grafts con-
tained the middle hepatic vein. The living donor grafts were
from right livers (n = 284), left livers (n = 17), or domino
livers (n = 3). Venovenous bypass was used intraopera-
tively in the first 115 patients, but it was not used thereafter
because the procedure was found not beneficial [7]. Intra-
operative hemodialysis was performed in seven patients
because of fluid overload, anuria, or difficulty maintaining a
stable hemodynamic state and acid–base balance.
After operation, the patients were routinely maintained
on mechanical ventilation until spontaneous breathing
effort was evident and hemodynamic stability had been
achieved. Renal support therapy was rendered when the
patients had oliguria, fluid overload, or increasing serum
levels of urea and creatinine.
The immunosuppressive protocol included steroid and
FK506 in the initial period of the study for up to patient no.
216 in our series, and thereafter a combination of FK506,
steroid, mycophenolate mofetil, and IL-2 receptor antago-
nist was used [8]. In the immediate postoperative period,
FK506 was prescribed only when renal function had
improved and adequate urine output was shown. After
about 3 months, monotherapy with FK506 was maintained.
Patients with hepatitis B continued to receive lifelong
lamivudine. Adefovir was added when YMDD mutant was
detected. Hepatitis B immunoglobulin was not given.
Patients with hepatitis C were not given any antiviral
treatment unless their liver graft showed evidence of
recurrent infection.
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In this study, possible causes of acute deterioration of
liver function and types of hepatic insults were documented
prospectively. Variceal bleeding was considered a mani-
festation of elevated portal pressure but not a hepatic insult
leading to the onset of acute-on-chronic liver failure.
Hepatorenal syndrome (type 1) was diagnosed by urine
sodium concentration of less than 10 mmol/l in the absence
of ultrasonographic evidence of obstructive uropathy or
parenchymal disease and lack of improvement in renal
function after plasma volume expansion [9]. The severity
of illness before liver transplantation was reflected by the
model for end-stage liver disease (MELD) score [10].
Hospital mortality was defined as death within the same
hospital admission for liver transplantation. All patients
were followed up regularly in the outpatient clinic by the
same team of surgeons. There was no default of follow-up.
The last census date for this study was August 31, 2008.
The overall patient and graft survival rates (all-cause
mortalities as an end point) were estimated by the life-table
method and compared between groups by the log-rank test.
Discrete variables were compared by the v2 test, and con-
tinuous variables were compared by the Mann–Whitney U
test. Stepwise logistic regression analysis was used to
define factors related to hospital mortality. Multivariate
analysis of factors of patient survival was performed with
the Cox proportional hazards model. All statistical analyses
were performed by SPSS, Version 12.0, for Windows
(SPSS Inc., Chicago, IL). A value P \ 0.05 was considered
statistically significant.
Results
Preoperative data
Male patients predominated in the two groups of patients
with acute-on-chronic liver failure (Table 1). For patients
with cirrhosis and acute deterioration, the median age was
similar to that of the patients with cirrhosis only, and they
were older than the patients with acute exacerbation of
chronic hepatitis B and those with fulminant hepatic fail-
ure. Reactivation of hepatitis B was the cause of deterio-
ration in all of the patients in group 2. Factors that induced
the viral reactivation were largely unknown, but steroid and
herbal medicine might have been responsible for 18 (36%)
patients (Table 2). Drugs were also a possible cause of
acute deterioration in 14 (14%) patients with cirrhosis
(group 3). Other factors included Wilson disease and
superimposed hepatitis E.
About 60% of the patients with acute-on-chronic liver
failure were intensive care unit bound before liver trans-
plantation (Table 1). The incidence was less than that of
the patients with fulminant hepatic failure (versus group 2,
P = 0.034; versus group 3, P = 0.006). Fifty-four percent
of the patients with acute exacerbation of chronic hepatitis
B and 36% of the cirrhotic patients with acute deterioration
lapsed into stage 3 or 4 coma before operation. The inci-
dence was lower for cirrhotic patients with acute deterio-
ration than that of the patients with fulminant hepatic
failure (P = 0.001). The median MELD scores of the
patients with acute exacerbation of chronic hepatitis B and
cirrhotic patients with acute deterioration were 37 and 35,
respectively. The values were similar to those of the
patients with fulminant hepatic failure and were definitely
higher than those of the patients with cirrhosis only
(Table 1).
Infection was identified before liver transplantation in
32% of the patients with acute exacerbation of chronic
hepatitis B and in 36.4% of the cirrhotic patients with acute
deterioration (Tables 1 and 3). The incidence was higher
than that of patients with fulminant hepatic failure (versus
group 2, P = 0.131; versus group 3, P = 0.038) and that of
patients with cirrhosis only (versus group 2, P \ 0.001;
versus group 3, P \ 0.001). Twenty-two (14.8%) patients
having acute-on-chronic liver failure had positive blood
culture results (Tables 1 and 3). Hepatorenal syndrome was
diagnosed in 16 (32%) patients with acute exacerbation of
chronic hepatitis B and in 41 (41.4%) cirrhotic patients
with acute deterioration. The incidence, though higher, was
not significantly higher than that of the patients with ful-
minant hepatic failure (27%) (versus group 2, P = 0.39;
versus group 3, P = 0.088). Six (16%), eight (16%), 20
(20%), and 0 patients in the four groups, respectively,
required preoperative hemodialysis. Seventeen (34%)
patients with acute exacerbation of chronic hepatitis B and
26 (26%) cirrhotic patients with acute deterioration
required mechanical ventilation. The incidence was lower
than that of the patients with fulminant hepatic failure
(versus group 2, P = 0.049; versus group 3, P = 0.003).
Intraoperative data
Three hundred four (62.4%) patients underwent LDLT
and 183 (37.6%) patients received DDLT. The propor-
tions of LDLT in the four groups were 83, 78, 65.7, and
56.4%, respectively (Table 4). There was no statistical
difference in the weight of the grafts they received,
irrespective of graft types. Cirrhotic patients with acute
deterioration had the highest blood transfusion require-
ment (versus group 1, P = 0.091; versus group 2,
P = 0.021; versus group 4, P \ 0.001). However, seven
(18.9%), five (10%), three (3%), and 66 (21.9%) patients
in groups 1, 2, 3, and 4, respectively, did not require
exogenous blood transfusion. Seven patients required
intraoperative hemodialysis. Five of them were cirrhotic
patients with acute deterioration.
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Pathological data
Hepatocellular carcinoma (HCC) was found in the liver
explants of 11 (11.1%) cirrhotic patients with acute dete-
rioration and 105 (34%) patients having cirrhosis only
(Table 4) but not in any of the explants from patients with
acute exacerbation of chronic hepatitis B. The finding of
HCC was incidental in five (45.5%) cirrhotic patients with
acute deterioration because thorough imaging of the liver
had not been carried out before the emergency transplan-
tation. However, almost 90% of the HCCs in this group
were in early stage. Etiologies of cirrhosis (according to
pathology of the explants) were similar in groups 3 and 4
(Table 5). The causes for fulminant hepatic failure are as
follows: acute hepatitis B in 11 patients, drug intoxication
in 12 patients, and unknown in 13 patients.
Table 1 Preoperative data
Fulminant hepatic
failure (n = 37)
Acute exacerbation of chronic
hepatitis B (n = 50)
Cirrhosis with acute
deterioration (n = 99)
Cirrhosis
(n = 301)
Male: Female 13:24 39:11 85:14 224:77
Age, median (range) 34 (19–60) 44 (17–63) 49 (17–66) 50 (17–68)
Pre-transplant status
Intensive care unit-bound 31 (83.8%) 32 (64%) 59 (59.6%) 12 (4%)
Hospital-bound 6 (16.2%) 17 (34%) 40 (40.4%) 67 (22.2%)
From home 0 1 (2%) 0 222 (73.8%)
MELD score, median (range) 37 (27–52) 37 (28–52) 35 (19–59) 17 (6–41)
Serum bilirubin (lmol/l),
median (range)
549 (91–879) 570 (321–957) 585 (86–1,209) 57 (9–957)
Serum ALT (IU/l),
median (range)
502 (33–7,150) 331 (34–2,389) 75 (14–4,020) 43 (7–270)
Serum AST (IU/l),
median (range)
281 (77–10,000) 178 (46–2,056) 117 (33–5,590) 64 (21–300)
Serum urea (mmol/l),
median (range)
2.4 (0.2–36) 4.25 (0.4–32) 6.8 (1.7–51.9) 4.9 (1.6–36.6)
Serum creatinine (lmol/l),
median (range)
82 (36–658) 103 (43–563) 115 (38–971) 86 (39–896)
White cell count (9109/l),
median (range)
9.35 (3.3–49.4) 9.35 (1.8–25.5) 7.85 (1.7–30.2) 4.2 (0.7–17.9)
Platelet count (9 109/l),
median (range)
129 (44–671) 127 (45–352) 62 (17–360) 57 (11–537)
INR, median (range) 4.4 (1.8–8.4) 3.5 (1.8–5.7) 2.8 (1.6–10.0) 1.5 (1.0–4.4)
Hepatic encephalopathy
Grade 0 2a 12 33 292
Grade 1 4 5 11 4
Grade 2 6 6 19 1
Grade 3 11 (29.7%) 15 (30%) 14 (14.1%) 2
Grade 4 14 (37.8%) 12 (24%) 22 (22%) 2
Preoperative infection 7 (18.9%) 16 (32%) 36 (36.4%) 6 (2.0%)
Respiratory tract 2 6 21 2
Urinary tract 4 4 11 1
Ascites 0 1 0 3
Blood 1 7 15 1
Other sites 0 0 8 3
Hepatorenal syndrome 10 (27%) 16 (32%) 41 (41.4%) 2 (0.7%)
Preoperative hemodialysis 6 (16.2%) 8 (16%) 20 (20.2%) 0 (0%)
Mechanical ventilation support 20 (54.1%) 17 (34%) 26 (26.3%) 2 (0.7%)
a Stage of hepatic encephalopathy was not clearly documented
MELD Model for end-stage liver disease, ALT alanine aminotransferase, AST aspartate aminotransferase, INR international normalized ratio
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Postoperative data
Early complications (\30 days) occurred in 62% of the
patients with acute exacerbation of chronic hepatitis B and
in 70.7% of the cirrhotic patients with acute deterioration
(Table 6). The incidence in the latter group was higher than
that of the patients with cirrhosis only (P \ 0.001). How-
ever, the incidence of reoperations for complications was
similar among the four groups, regardless of whether the
initial operations were LDLT or DDLT. Patients with
acute-on-chronic liver failure had a higher need for he-
modialysis after operation. Their durations of intensive
care unit stay were also longer than those of the patients
having cirrhosis only (versus group 2, P = 0.014; versus
group 3, P \ 0.001). However, among patients in groups 1,
2, and 3, patients with acute exacerbation of chronic hep-
atitis B had the shortest hospital stay. Their recovery of
liver and renal functions was rapid and similar to that of the
patients with cirrhosis (Fig. 1). Patients with acute-on-
chronic liver failure had significantly higher serum creati-
nine levels on postoperative days 1, 2, and 3.
Survival data
The hospital mortality rates were 4.0 and 5.1% for patients
with acute exacerbation of chronic hepatitis B and cirrhotic
patients with acute deterioration, respectively (Table 6).
The hospital mortality rate of all patients with acute-on-
chronic liver failure was 4.7%, which was not significantly
higher than that of patients with fulminant hepatic failure
(2.7%) and that of patients with cirrhosis only (7%). Five
(71.4%) of the seven patients who needed intraoperative
hemodialysis died. Causes of hospital mortality are listed in
Table 7. Multivariate analyses of preoperative parameters
(age, pretransplant status, MELD score, platelet count,
Table 2 Possible factors leading to acute exacerbation of hepatitis B
and acute deterioration of cirrhotic patients
Acute exacerbation of
hepatitis B (n = 50)
Cirrhosis with acute
deterioration (n = 99)
Unknown 30 71
Herbal medicine 15 11
Steroid 3 2
Interleukin 1 0
Cyclosporine A
withdrawal
1 0
Hepatitis E infection 0 1
YMDD mutant 0 3
Withdrawal of
nucleoside
analogue
0 1
Wilson disease 0 3
Unknown hepatitis C
virus
0 1
Post-hepatectomy
portal vein
thrombosis
0 1
Anti-tuberculosis
drugs
0 1
Unknown Wilson
disease
0 4
Table 3 Bacteriology of cultures of fluid according to patient groups and sites of origin
Bacteria Fungus
MRSA MSSA E. coli Klebsiella Pseudomonas Others Candida
Patient group
Fulminant hepatic failure 1 0 2 2 0 2 2
Acute exacerbation of chronic hepatitis B 0 1 2 3 1 11 3
Cirrhosis with acute deterioration 9 10 8 5 3 19 14
Cirrhosis 1 0 2 0 0 2 2
Site of origin
Respiratory tract 4 6 1 5 3 18 14
Urinary tract 2 0 8 4 0 9 7
Ascites 2 0 1 0 1 0 1
Blood 3 3 8 2 1 7 1
Other sites 1 2 2 0 1 1 5
MRSA Methicillin-resistant staphylococcus aureus, MSSA Methicillin-sensitive staphylococcus aureus
Others: Coagulase negative staphylococcus (n = 1), Streptococci vividans (n = 1), a-hemolytic streptococcus (n = 16), Enterococcus fecalis
(n = 2), Enterococcus species (n = 10), Diphtheroid bacilli (n = 1), Enterobacter agglomeraus (n = 1), Proteus sp. (n = 1), Moraxella species
(n = 1), Propionibacterium acnes (n = 1), Acinetobacter baumannii (n = 6), Morganella morganii (n = 1), Nisseria species (n = 2),
Stomatococcus mucilaginosus (n = 2), Clostridium difficile (n = 1), Hemophilius parahemolyticus (n = 1), Mycobacterium tuberculosis
(n = 1), Acinetobacter species (n = 1), and Aeromonas hydrophilia (n = 1)
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presence of hepatic encephalopathy, infection or hepato-
renal syndrome, and need for preoperative hemodialysis or
mechanical ventilatory support), intraoperative parameters
(LDLT versus DDLT, graft weight-to-estimated standard
liver volume ratio, graft weight-to-recipient body weight
ratio, volume of blood transfusion, volume of fresh frozen
plasma transfusion, platelet concentrates, and need for
intraoperative hemodialysis), and diagnosis groups showed
that intraoperative blood transfusion volume was the only
significant factor that could predict hospital mortality
(relative risk, 1.119; 95% confidence interval, 1.077–
1.163). According to discriminant analysis, blood transfu-
sion volume of 14.5 l was the cutoff level that could pre-
dict hospital mortality.
The median follow-up durations of the four groups of
patients were 73.4, 53.9, 55.5, and 46.9 months, respec-
tively, and the ranges were 3.3–172.1, 0.37–149.1, 0.33–
149.9, and 0–179.1 months, respectively. There was no
default in follow-up. The 1-year graft survival rate excee-
ded 90% in all four groups of patients. The estimated
5-year survival rates of patients with acute exacerbation of
chronic hepatitis B and cirrhotic patients with acute dete-
rioration were 93.2 and 90.5%, respectively (Table 6).
Causes of late mortalities are listed in Table 8. According
to the Cox proportional hazards model, factors leading to
Table 4 Intraoperative data
Fulminant hepatic
failure (n = 37)
Acute exacerbation of chronic
hepatitis B (n = 50)
Cirrhosis with acute
deterioration (n = 99)
Cirrhosis
(n = 301)
LDLT: DDLT 31:6 38:12 65:34 170:131
Graft weight/ESLV (%) 53.6 (27.4–117.1) 52.7 (36.9–135.5) 54.0 (28.4–140.8) 59.3 (27.3–186.8)
Graft weight/recipient body
weight (%)
1.05 (0.53–1.98) 0.99 (0.64–2.65) 1.01 (0.49–3.07) 1.14 (0.49–4.29)
Living donor graft weight/ESLV
(%)
52.2 (27.4–89.4) 49.7 (36.9–86.9) 46.8 (28.4–68.9) 49.0 (27.3–79.5)
Living donor graft weight/
recipient body weight (%)
0.95 (0.53–1.92) 0.90 (0.64–1.95) 0.87 (0.49–1.31) 0.91 (0.49–1.51)
Blood transfusion units, median
(range)
7 (0–15) 4.5 (0–30) 7 (0–58) 5 (0–108)
No. of patients without blood
transfusion
7 (18.9%) 5 (10%) 3 (3%) 66 (21.9%)
FFP transfusion units, median
(range)
12 (2–26) 13 (3–37) 13 (5–48) 8 (0–66)
Platelet transfusion units, median
(range)
6 (0–20) 5 (0–32) 12 (0–53) 10 (0–51)
Intraoperative hemodialysis 1 (2.7%) 1 (2.0%) 5 (5.1%) 0 (0%)
Concomitant hepatocellular
carcinoma
0 (0%) 0 (0%) 11 (11.1%) 105 (34.9%)
Incidental hepatocellular
carcinoma
0 0 5 (45.5%) 6 (5.7%)
TNM stage I 0 0 5 (45.5%) 41 (39%)
TNM stage II 0 0 5 (45.5%) 51 (48.6%)
TNM stage III 0 0 1 (9.1%) 12 (11.4%)
TNM stage IV 0 0 0 (0%) 1 (1.0%)
LDLT living donor liver transplantation, DDLT deceased donor liver transplantation, ESLV estimated standard liver volume, FFP fresh frozen
plasma, TNM tumor-node-metastasis
Table 5 Etiologies of cirrhosis based on explant pathology
Cirrhosis with acute
deterioration (n = 99)
Cirrhosis
(n = 301)
Hepatitis B 85 (85.9%) 222 (73.8%)
Hepatitis C 2 (2%) 27 (9%)
Hepatitis B and C 1 (1%) 2 (0.7%)
Wilson disease 7 (7.1%) 4 (1.3%)
Autoimmune
hepatitis
1 (1%) 3 (1%)
Alcoholic cirrhosis 2 (2%) 14 (4.7%)
Idiopathic cirrhosis 1 ((1%) 6 (2%)
Secondary biliary
cirrhosis
0 (0%) 6 (1.7%)
Primary biliary
cirrhosis
0 (0%) 16 (5.3%)
Overlapping
syndrome
0 (0%) 1 (0.3%)
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late mortality were MELD score (relative risk, 0.959; 95%
confidence interval, 0.935–0.984) and the need for intra-
operative hemodialysis (relative risk, 11.415; 95%
confidence interval, 2.471–52.765). Because the MELD
score had a paradoxical effect on late mortality, a further
analysis was carried out. It was identified that many HCC
Table 6 Postoperative and survival data
Fulminant hepatic
failure (n = 37)
Acute exacerbation of chronic
hepatitis B (n = 50)
Cirrhosis with acute
deterioration (n = 99)
Cirrhosis
(n = 301)
Early complications
(\30 days)
26 (70.3%) 31 (62%) 70 (70.7%) 158 (52.5%)
Re-operation 10 (27%) 8 (16%) 22 (22%) 51 (16.9%)
LDLT 8 (25.8%) 8 (21%) 15 (23%) 24 (14.1%)
DDLT 2 (33.3%) 0 (0%) 7 (20.5%) 27 (20.6%)
Postoperative hemodialysis 2 (5.4%) 5 (10%) 11 (11.1%) 0 (0%)
Intensive care unit days,
median (range)
6 (1–35) 6 (1–37) 5 (1–125) 4 (1–99)
Hospital days, median
(range)
29 (8–183) 18 (10–79) 24 (8–210) 17 (0–1,163)
Hospital mortality 1 (2.7%) 2 (4.0%) 5 (5.1%) 21 (7%)
One-year graft survival rate 97.3% 94% 95% 89.4%
Three-year graft survival rate 91.8% 94% 90.5% 81.7%
Five-year graft survival rate 87.4% 91.2% 90.5% 76.2%
Re-transplantation 3 (8.1%) 1 (2%) 0 (0%) 11 (3.7%)
One-year overall survival
rate
97.3% 96% 95% 90.7%
Three-year overall survival
rate
91.8% 96% 90.5% 83.7%
Five-year overall survival
rate
91.8% 93.2% 90.5% 79.3%
Fig. 1 Median preoperative and postoperative a serum total bilirubin levels, b international normalized ratio (INR) values, c platelet counts, and
d creatinine levels of the four groups of patients
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patients who died of tumor recurrence had low MELD
scores. After excluding the HCC patients, repeated multi-
variate analyses showed that graft type (i.e., living donor
graft) was associated with better survival (relative risk,
0.509; 95% confidence interval, 0.265–0.98).
Further analysis was performed to exclude the influence
of HCC on long-term survival. After excluding the HCC
patients in groups 3 and 4, the difference in survival was
still significant, with group 3 patients having better long-
term survival rates (Fig. 2).
Fourteen patients underwent retransplantation because
of primary non-function (n = 1), hepatic artery thrombosis
(n = 2), portal vein thrombosis (n = 5), bile duct stricture
(n = 1), unknown hepatitis (n = 2), recurrent hepatitis B
(n = 2), and recurrent hepatitis C (n = 2). Because the
retransplantation rate was low, the overall patient survival
rates were similar to the graft survival rates (Table 6). The
overall survival rates of patients receiving DDLT and those
having LDLT were not dissimilar in all the four groups
(Fig. 3).
Table 7 Causes of hospital
mortalities
Fulminant hepatic
failure (n = 37)
Acute exacerbation of
chronic hepatitis B (n = 50)
Cirrhosis with acute
deterioration (n = 99)
Cirrhosis
(n = 301)
Septic
complications
0 1 2 4
Cardiac
complications
0 0 0 4
Respiratory
complications
0 0 0 1
Biliary leakage 0 0 0 1
Autoimmune
disorders
1 0 0 1
Intracranial
pathology
0 0 1 5
Multiorgan
failure
0 0 1 1
Graft
complications
0 0 0 3
Severe
hemorrhage
0 0 0 1
Intraabdominal
complications
0 1 1 0
Table 8 Causes of late
mortalities
Fulminant hepatic
failure (n = 37)
Acute exacerbation of
chronic hepatitis B (n = 50)
Cirrhosis with acute
deterioration (n = 99)
Cirrhosis
(n = 301)
Rejection 1 0 0 2
Graft
complications
2 0 2 2
Hepatitis B/C
infection
0 0 0 3
Sepsis 1 0 2 4
Cardiac
complications
0 0 0 1
Respiratory
complications
0 0 0 5
Hematological
disorders
0 0 0 3
Gastrointestinal
bleeding
0 0 0 3
Terminal
malignancy
0 1 1 15
Others 1 0 0 2
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Discussion
The study demonstrated that patients with acute-on-chronic
liver failure were at high risk of dying because of a high
incidence of concomitant infection (including septicemia)
and renal and respiratory failure. The severity of pre-
transplant illness of the patients with acute-on-chronic liver
failure was reflected by their high MELD scores. Such
patients probably belonged to status IIA in the United
Network for Organ Sharing classification of waiting list for
liver transplantation. However, with timely liver trans-
plantation, particularly with the availability of LDLT, most
of them were salvaged with rapid normalization of hepatic
and renal functions. Their long-term survival rates are also
satisfactory. Comparing them with the patients with ful-
minant hepatic failure and those with cirrhosis only, all
treated in the same center and period, the outcome is
equally satisfactory. Compared with the scanty data from
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Fig. 2 Cumulative survival curves of non-hepatocellular carcinoma
cirrhotic patients with and without acute deterioration
Fig. 3 Cumulative survival curves of a patients with fulminant
hepatic failure, b patients with acute exacerbation of chronic hepatitis
B, c cirrhotic patients with acute deterioration, and d patients with
cirrhosis only. Comparison between patients who underwent deceased
donor liver transplantation (DDLT) and those who underwent living
donor liver transplantation (LDLT)
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the literature, the outcome of the patients reported in this
study is probably superior [11–14].
The patients with acute-on-chronic liver failure had two
hepatic insults: acute liver injury on top of chronic liver
damage. Those with chronic hepatitis B had various
degrees of liver fibrosis but preserved liver function. Their
pretransplant conditions were similar to those of the
patients with fulminant hepatic failure. However, because
their clinical deterioration was less fulminant, the inci-
dence of intensive care unit admission in this group was
lower. Patients having established cirrhosis with superim-
posed acute liver injury represented the highest risk group.
They might be nutritionally depleted or might have suf-
fered ill effects of portal hypertension. In previous studies,
the outcome of liver transplantation for these patients was
unfavorable [11–14]. The unfavorable outcome was prob-
ably related to the timing of liver transplantation and graft
quality. If liver transplantation could be carried out before
irreversible multiorgan failure, and if the liver grafts were
optimal in function, as shown in this series, even patients
with preoperative infection and renal and respiratory fail-
ure could be salvaged. The results of our patients who
underwent LDLT are favorable because nearly all our
living grafts contained the middle hepatic vein, which
allows uniform and complete venous drainage of the graft
[15].
In our center, we offer options of both LDLT and DDLT.
Supply of deceased donor liver grafts in our locality is
scarce. The donor rate is about three per million population
per year. Patients on the waiting list for DDLT are priori-
tized by MELD score. Thus, patients with acute-on-chronic
liver failure are always on the top of the list and receive
deceased donor grafts once they are available. Nevertheless,
only a fortunate few can be supported in the intensive care
unit and undergo DDLT in time. The molecular adsorbents
recirculation system has been especially useful in bridging
some of our patients to DDLT [16].
In this study, the 5-year overall survival rate of patients
with acute-on-chronic liver failure exceeded 90%. Patients
with cirrhosis only had less favorable long-term survival
because many of them developed HCC and died of tumor
recurrence. HCC was also present in 11% of the cirrhotic
patients with acute deterioration, but their long-term sur-
vival was not affected, probably because the tumors were
in early stage. However, even with exclusion of HCC
patients, the cirrhotic patients with acute deterioration still
had significantly better survival rates than the patients with
cirrhosis only. The exact reason is not known.
In conclusion, the short-term and long-term survival
rates after liver transplantation for acute-on-chronic liver
failure are similar to those after transplantation for other
liver conditions. Timely transplantation, especially by
LDLT in regions with scarcity of deceased donor livers, is
the only modality that can salvage patients of acute-on-
chronic liver failure. However, the timing and indication
for transplantation for this illness are not yet well defined.
In the present study, the timing was determined according
to the King’s College Hospital criteria. Patients with acute
exacerbation of chronic hepatitis B demonstrate many
clinical features similar to those demonstrated by patients
with fulminant hepatic failure, so the King’s College
Hospital criteria may be applicable to them. For cirrhotic
patients with acute deterioration, their underlying cirrhosis
status may prevent them from recovering spontaneously.
For such patients, the King’s College Hospital criteria may
not be applicable. In fact, there exists a set of criteria
established previously for acute-on-chronic liver failure
[17], but it carries the deficiency that the criteria were
established on a relatively small patient database. At
present, a large-scale study based on data of all patients
with acute-on-chronic liver failure admitted to our center is
on the way. Identification of factors predicting mortality
and the need for liver transplantation will allow earlier
transplantation and a higher salvage rate.
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